CD274 and breast carcinoma: Programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) immunotherapy is one of the most promising treatments for breast cancer, relying on and helping the patient’s immune system to fight cancers2–4, and offering a personalized and less invasive alternative therapy.